Announcement on Subsidiary Obtaining Notice of Approval for Drug Clinical Trials
Release time:
2021-05-20
Securities Code: 600668 Securities Abbreviation: Jianfeng Group No: pro 2021-001
Zhejiang Jianfeng Group Co., Ltd.
Announcement on Subsidiaries Obtaining Drug Clinical Trial Approval Notice
The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assumes individual and joint responsibility for the truthfulness, accuracy and completeness of its contents .
Important Note:
- Company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results.
- Risk Warning: Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links of products from development, clinical trials to production are susceptible to some uncertain factors, clinical trial progress, There are many uncertainties in the results and the future product market competition situation.
1. Summary
Recently, Zhejiang Erying Pharmaceutical Co., Ltd. (hereinafter referred to as "Erying Company") and , the controlling subsidiary of Zhejiang Jianfeng Pharmaceutical Co., Ltd., the controlling subsidiary of the Company, received the Notice of Approval for Clinical Trials of Drugs approved and issued by the State Drug Administration. The relevant details are hereby announced as follows:
2. drug basic information content
drug name: acetaminophen suppository
English name: Paracetamol Suppositories
dosage form: suppository
application classification: generic drug application
specification: 75mg , 125mg
registration classification: chemical drugs category 3
applicant: Zhejiang erying drug co., ltd.
approval conclusion: "according to the the People's Republic of China drug administration law and relevant regulations, after examination, the acetaminophen suppository accepted on 2020 5 February 13 meets the relevant requirements for drug registration, it is recommended that the bioequivalence study of this product be carried out in healthy adults with a single fasting dose, and that the study of BE be exempted under different specifications to meet pharmaceutical requirements."
3. Drug Research and Development and Investment
Acetaminophen Suppository is an antipyretic analgesic developed by Erying Company. Its registered classification belongs to chemical drug 3 . Acetaminophen Suppository is indicated for fever caused by common cold or influenza in children, and is also used for relieving mild to moderate pain such as headache, arthralgia, migraine, toothache, myalgia and neuralgia. As of the date of this announcement, the accumulated research and development expenses and technical investment of the project totaled about RMB ,788.09 . Market Situation of
4. Similar Drugs
Acetaminophen Suppository was first developed by German Bene Company and listed in Germany in 1960 . In 2019 , the dosage of German acetaminophen Suppository was about 1.08 .6 billion tablets (data source: IMS ). At present, paracetamol suppositories of infant specifications have been listed in many countries in the world. At present, paracetamol suppositories of 125 mg , 150 mg , 300 mg and 600 mg have been listed in China, of which 125 mg and 150 mg are used for fever caused by common cold or influenza in children aged 1-6 , no paracetamol suppositories exist for infants and young children aged 0-1 years. Acetaminophen suppository (75 mg ) developed by Erying Company is suitable for antipyretic and analgesic treatment for infants aged 0-1 years old in China. Acetaminophen suppository (125 mg ) is suitable for infants aged 6 months to 2 years old (administered according to age and weight). Scientifically administered acetaminophen suppository will be provided for infants aged 0-2-2-116 years old. Approval Procedures to Be Performed for Listing of 5. Products
Er Ying Company will conduct clinical trials (bioequivalence studies) according to the requirements of the Notice of Approval of Drug Clinical Trials. After the clinical trials are completed, it will apply for production. After passing the review and approval of the State Food and Drug Administration and obtaining the approval documents for drug production, it can produce
products and go on sale. 6. Impact on Listed Companies and Risk Tips
The company's approval notice for drug clinical trials will not have a significant impact on the company's recent operating results. Due to the particularity of drug research and development, the pre-development of drugs and the long cycle and many links from development, clinical trials to production of products are easily affected by some uncertain factors. There are many uncertainties in the progress and results of clinical trials and the future product market competition situation. The company will be based on the progress of research and development in a timely manner to fulfill the obligations of information disclosure, so that the majority of investors pay attention to investment risks.
hereby announce
Zhejiang Jianfeng Group Co., Ltd. Board of Directors
January 6, 2001
More information
Representatives of the 20th Congress preached the 20th Congress at the peak.
On the afternoon of November 11, a special lecture on the spirit of the Party's 20th Congress was held in the conference room of the Peak Building. Yang Xiayun, a representative of the 20th National Congress, walked into the peak and preached his understanding of the spirit of the 20th National Congress for Party members through personal experience.
2022
11-23
The group party committee organizes and learns the twenty spirits.
On the afternoon of October 28, the party Committee of the group organized all members to hold a special study meeting to earnestly study and understand the communique of the first plenary session of the 20th central Committee of the communist party of China and the revision of the party constitution. Jiang Xiaomeng, Secretary of the Party committee of the group, stressed at the study meeting that the 20th National Congress of the Communist Party of China has drawn a grand blueprint for building a socialist modern country in an all-round way, opened a new chapter in the era of national development, and pointed out the direction for the future development of enterprises. Party organizations at all levels of the group should pay full attention to and earnestly implement it, actively organize party members and cadres to learn the spirit of the spirit of the 20th National Congress, And to guide the future work practice.
2022
11-01
Spike Party Members and Cadres Watch the Opening Meeting of the 20th Congress
At 10 a.m. on October 16, the 20th National Congress of the Communist Party of China was solemnly opened in the Great Hall of the People in Beijing. Xi Jinping delivered a report to the Party's 20th National Congress on behalf of the 19th Central Committee. The group company attaches great importance to and carefully deploys, and organizes all party members and management backbones of the group headquarters and subsidiaries to watch the live broadcast of the opening meeting through the Internet, TV and other methods.
2022
10-23
Jiang Xiaomeng was hired as the "Shuanglong Escort" entrepreneurial mentor.
On September 16, Jiang Xiaomeng, Secretary of the Party committee and chairman of the group company, was employed as the entrepreneurial mentor of "Shuanglong escort" at the launching ceremony of the special action of "Shuanglong escort steady progress and quality improvement" held in Jinhua City and the promotion meeting of innovative products of key talent enterprises in Jinhua City.
2022
09-27
From August 18th to 19th, the 12th Congress of the Zhejiang Federation of Industry and Commerce was held in Hangzhou, and the 12th leadership of the Provincial Federation of Industry and Commerce was elected. Jiang Xiaomeng, Secretary of the Party Committee and Chairman of the Group, was re-elected as Vice President of Zhejiang Chamber of Commerce.
2022
09-01
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page